Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | DPP3 | Q9NY33 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 5/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8280370 | 1.00 | DPP4 (0.39) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8253477 | 0.95 | DPP4 (0.38) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8247918 | 0.95 | DPP4 (0.38) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8279416 | 0.91 | PEPD (0.42) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8240611 | 0.89 | DPP4 (0.38) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8240265 | 0.89 | DPP4 (0.39) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8251134 | 0.89 | PEPD (0.36) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8246714 | 0.88 | ELANE (0.37) | OPRM1 | |
| SCHEMBL8244610 | 0.88 | ELANE (0.39) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8278695 | 0.88 | ELANE (0.39) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730142-B1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-1730110-B1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2006130687-A2 | LIVER/PLASMA CONCENTRATION RATIO FOR DOSING HEPATITIS C VIRUS PROTEASE INHIBITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130553-A2 | HCV PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130628-A2 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130626-A2 | METHOD FOR MODULATING ACTIVITY OF HCV PROTEASE THROUGH USE OF A NOVEL HCV PROTEASE INHIBITOR TO REDUCE DURATION OF TREATMENT PERIOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130554-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |